Gemtuzumab ozogamicin is a targeted therapy medication used to treat acute myeloid leukemia. It works by attaching to cancer cells and delivering a substance that can kill them.

Cytarabine is a chemotherapy medication that works by interfering with DNA synthesis, which helps stop cancer cells from growing and dividing.

Mitoxantrone is a chemotherapy medication that works by blocking an enzyme called topoisomerase II, which cancer cells need to divide and grow.

Liposomal daunorubicin is a special form of chemotherapy medication enclosed in tiny fat particles, which helps deliver the medicine more effectively to cancer cells while potentially reducing side effects.

Fludarabine is a chemotherapy medication that works by slowing or stopping the growth of cancer cells.

Busulfan is a chemotherapy medication used before bone marrow transplants to prepare the body by destroying abnormal cells in the bone marrow.

Cyclophosphamide is a chemotherapy medication that works by damaging the DNA of cancer cells, which prevents them from multiplying.

Acute Myeloid Leukemia (AML) – A blood and bone marrow cancer that develops when immature blood cells called myeloid cells begin growing abnormally. These abnormal cells build up in the bone marrow and interfere with the production of normal blood cells. The disease progresses rapidly, affecting the production of red blood cells, white blood cells, and platelets.

High-Risk Myelodysplastic Syndrome (MDS) – A group of blood disorders where bone marrow fails to produce enough healthy blood cells. In high-risk MDS, more than 10% of cells in the bone marrow are immature cells called blasts. The condition causes the bone marrow to produce abnormal blood cells that don’t develop properly and can’t function normally.

Myeloid Sarcoma – A rare condition where myeloid cells form a tumor mass outside the bone marrow. The abnormal myeloid cells can develop in various parts of the body, forming solid tumors in soft tissues or bones. This condition can occur on its own (de novo) or develop as a result of other blood disorders (secondary).